The central role of this pathway in tumor pathobiology has necessitated the development of a number of currently available medications, including farnesyl transferase inhibitors such as salirasib, BRAF inhibitors such as vemurafenib, MEK inhibitors such as trametinib, and ERK inhibitors such as ulixertinib, which warrant further study as therapy for childhood vascular tumors. This evidence concerns the gene MAP2K7 and neoplasm.